Premier Research: International Multiple Myeloma Treatment Study Highlighted By ASCO 2026

The American Society of Clinical Oncology (ASCO) is highlighting new research from a collaboration between Premier Applied Sciences® (PAS) and Mango Sciences Inc. in conjunction with ASCO’s 2026 annual meeting.

The abstract, titled “Multiple Myeloma in the United States and India: An International, Collaborative Study Comparing Patient Characteristics and Treatment Patterns,” presents findings from a retrospective, real-world data study examining treatment patterns of patients with multiple myeloma (MM) in the United States and India across two distinct healthcare databases.

The abstract was accepted under the ASCO 2026 Annual Meeting track for Hematologic Malignancies – Plasma Cell Dyscrasia, with a focus on cell therapy, bispecific antibodies and autologous stem cell transplantation for multiple myeloma and other plasma cell disorders.

About the Study

Multiple myeloma is one of the most common hematological malignancies globally, with an expanding array of treatment options including targeted therapies, bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapies. Despite this therapeutic progress, significant differences in patient demographics, access to care and treatment utilization persist across geographies — and are not yet fully understood.

The PAS research team, in collaboration with Mango Sciences, analyzed real-world data from patients newly diagnosed with MM over a 21-month period and followed for at least one year. U.S. patient data was sourced from hospital chargemaster records in the Premier Healthcare Database (PHD), while Indian patient data was drawn from electronic medical records in Mango Sciences’ Healthcare Database.

Key Findings:

The study identified 77,901 patients with MM in the U.S. and 2,268 patients in India:

• U.S. patients were older and more likely to have health insurance.
• A higher proportion of Indian patients received MM-related drug treatment. 
• Corticosteroids were the most common therapy in both countries.
• Proteasome inhibitors were more commonly used in India, while U.S. patients were more likely to receive recently launched therapies including daratumumab, bispecific agents and CAR-T therapy.

These findings provide real-world evidence of consistent frontline care across two distinct healthcare databases covering healthcare systems in the United States and India. They also illuminate how differences in patient demographics and access may influence treatment utilization — particularly for newer, innovative therapies.

Real-World Data for Cross-National Comparisons

This research demonstrates the power of the PHD to generate meaningful real-world evidence. When paired with international data, such as the Indian patient data from Mango Sciences, it unlocks the ability to draw cross-national comparisons. These broader insights can inform how the global oncology community approaches treatment access, care delivery and outcomes.

The full abstract is published on the ASCO 2026 website.

More Research from Premier Applied Sciences

Premier Applied Sciences is a trusted research and analytics partner for organizations working to improve the quality, safety and cost-effectiveness of care. With cross-sector expertise spanning healthcare, life sciences, government and academia, PAS combines an expert team of clinicians and data scientists with a best-in-class, HIPAA-compliant database to conduct applied and prospective research, including clinical trials, on the most pressing questions in healthcare.

Learn more about our prospective and applied research powered by the vast data available in the Premier Healthcare Database.